Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Neurology · APP-Related Amyloidosis

Monitoring, MRI Scans, and Long-Term Care

At a Glance

MRI follow-up for APP-related amyloidosis is individualized based on a person’s variant, symptoms, and history of brain bleeding. Scans look for microbleeds, surface blood staining, small surface leaks, and white matter changes to help guide long-term care and risk reduction.

Managing APP-related amyloidosis is a marathon, not a sprint. Because the condition involves the gradual buildup of amyloid protein over decades, long-term care focuses on consistent monitoring to detect changes early and adjust your risk-reduction strategy [1]. While the uncertainty of the future can be difficult, regular surveillance provides a roadmap for your care team.

The Long Runway: Preclinical Changes

One of the most striking features of APP-related amyloidosis, particularly the Dutch-type, is how long the disease is present before it causes noticeable symptoms.

  • A 14-Year Window: Research in specific hereditary Dutch-type cohorts has shown that changes in the brain’s white matter and blood vessel reactivity can be detected more than 14 years before the average age of a person’s first symptomatic brain bleed [2][3].
  • Early Markers: Changes in spinal fluid (CSF) and subtle white matter injury often appear as early as age 30, while “hemorrhagic” markers (like microbleeds) typically do not appear until after age 41 [3][4].
  • Cognitive Stability: Many people remain cognitively stable or experience only very subtle changes in executive function (like multi-tasking) for years before any major events occur [5][6].

MRI Surveillance: Tracking the Footprints

Routine MRI scans are the primary tool for monitoring your brain’s health. While there is no “one-size-fits-all” schedule, your surveillance schedule will be individualized based on your specific variant, symptoms, and specialist judgment [7][8].

Your scans will focus on key “markers” that help predict future risk:

  1. Cortical Superficial Siderosis (cSS): This staining on the brain’s surface is a powerful predictor. If the siderosis is “disseminated” (spread across multiple areas), the risk of a future bleed is significantly higher [9][10].
  2. Convexity Subarachnoid Hemorrhage (cSAH): A small leak of blood on the brain’s surface. Even if it doesn’t cause major symptoms, its presence is a strong signal that the vessels are under stress [11][10].
  3. White Matter Hyperintensities (WMH): These appear as bright spots on certain MRI sequences (FLAIR). They represent chronic blood flow issues but are non-specific findings that can also be caused by standard high blood pressure [12][13].

Understanding Recurrence Risk

For those who have already experienced an Intracerebral Hemorrhage (ICH), the question of “when will it happen again?” is often the biggest source of anxiety.

  • Recurrence Rate: In symptomatic hereditary Dutch-type cohorts, the risk of a second or third bleed is high, with an average interval of about 27 months between the first and second events [14]. These are cohort averages, and your individual schedule and prognosis may vary.
  • Predictors: Your risk of a second bleed is not just “luck”—it is closely tied to the MRI markers mentioned above. Having multiple microbleeds (more than 10) or disseminated siderosis increases the likelihood of a recurrence [15][9].
  • Cognitive Progression: While a bleed is a sudden event, cognitive decline is often much slower. Subtle changes in memory and processing speed may occur over several years following a major bleed [6].

Managing “Scanxiety”

“Scanxiety”—the intense worry that precedes and follows an imaging appointment—is a very real experience for patients with rare genetic conditions [16].

  • Acknowledge the Stress: It is normal to feel a sense of dread or “waiting for the other shoe to drop” before a scan. This anxiety can affect your sleep, mood, and daily life [17][18].
  • Practical Coping: Research suggests that reducing the time between the scan and the results is the most effective way to lower anxiety [16]. Ask your doctor if they can schedule a “results” call or portal message within 24–48 hours of the scan.
  • Preparation Matters: Using relaxation techniques, listening to music, or having a clear explanation of the procedure beforehand can help reduce physical distress during the MRI itself [19][20].
  • The Power of Peer Support: Connecting with others who face the same monitoring schedule—such as through the DIAN network—can provide a sense of community that helps normalize the experience [21][22].
Marker What it looks like on MRI Meaning for Your Care
Microbleeds Small black dots Cumulative sign of vessel damage
cSS (Siderosis) Dark lines on brain surface High-risk marker for future bleeds
WMH Bright white patches Sign of chronic blood flow issues
Calcifications Bright spots (on CT) Marker of some specific variants

Your MRI is not just a search for “bad news”—it is a tool that helps your doctor tailor your blood pressure management and lifestyle goals to keep your brain as healthy as possible for as long as possible.

Common questions in this guide

How often should I have an MRI for APP-related amyloidosis?
There is no single MRI schedule for everyone with APP-related amyloidosis. Your neurologist may tailor the interval to your genetic variant, symptoms, prior bleeding, MRI findings, and overall risk, and may recommend sequences such as SWI or T2*.
Which MRI findings can raise the risk of another brain bleed?
Disseminated cortical superficial siderosis, convexity subarachnoid hemorrhage, and numerous cerebral microbleeds are associated with a higher risk of recurrent bleeding. More than 10 microbleeds may be especially concerning, but your specialist must interpret these findings in the context of your complete scan and history.
What do white matter hyperintensities mean on an MRI?
White matter hyperintensities are bright areas seen on certain MRI sequences, such as FLAIR. They can reflect long-term blood-flow or vessel changes, but they are not specific to APP-related amyloidosis and can also occur with high blood pressure.
Can MRI show changes before symptoms begin?
In some Dutch-type hereditary cohorts, changes in white matter and blood-vessel reactivity were detected more than 14 years before the average first symptomatic brain bleed. These are group findings and cannot predict exactly when symptoms will occur for one person.
How can I manage anxiety before or after an MRI?
Ask whether your results can be discussed by phone or sent through a patient portal within 24 to 48 hours after the scan. Learning what to expect, using relaxation techniques or music, and connecting with peer-support networks may also make scan-related anxiety easier to manage.
When should a new headache or amyloid spell be checked?
A new amyloid spell or a headache that is different from your usual pattern should be reported promptly to your care team rather than automatically waiting for a routine scan. Your clinician can decide whether you need urgent assessment or MRI based on the symptoms and your medical history.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on APP-related brain and vascular amyloidosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What MRI interval do you recommend for my specific situation, and will we use SWI or T2* sequences every time?
  2. 2.Looking at my most recent scan, do I have 'disseminated' cortical superficial siderosis or convexity subarachnoid hemorrhages, and how do these affect my risk for a future bleed?
  3. 3.How do you differentiate between 'routine' white matter changes and those that might indicate a more rapid progression of my condition?
  4. 4.If I experience a new 'amyloid spell' or a different type of headache, should I wait for my scheduled scan or come in for an urgent MRI?
  5. 5.Is there a way for me to receive my radiology results more quickly to help manage the anxiety of waiting for news?

References

References (22)
  1. 1

    Phenotype and imaging features associated with APP duplications.

    Grangeon L, Charbonnier C, Zarea A, et al.

    Alzheimer's research & therapy 2023; (15(1)):93 doi:10.1186/s13195-023-01172-2.

    PMID: 37170141
  2. 2

    Progressive White Matter Injury in Preclinical Dutch Cerebral Amyloid Angiopathy.

    Shirzadi Z, Yau WW, Schultz SA, et al.

    Annals of neurology 2022; (92(3)):358-363 doi:10.1002/ana.26429.

    PMID: 35670654
  3. 3

    Temporal Ordering of Biomarkers in Dutch-Type Hereditary Cerebral Amyloid Angiopathy.

    Koemans EA, Rasing I, Voigt S, et al.

    Stroke 2024; (55(4)):954-962 doi:10.1161/STROKEAHA.123.044688.

    PMID: 38445479
  4. 4

    Progression of cerebral amyloid angiopathy: a pathophysiological framework.

    Koemans EA, Chhatwal JP, van Veluw SJ, et al.

    The Lancet. Neurology 2023; (22(7)):632-642 doi:10.1016/S1474-4422(23)00114-X.

    PMID: 37236210
  5. 5

    Cognition in (pre)symptomatic Dutch-type hereditary and sporadic cerebral amyloid angiopathy.

    van Dort R, Kaushik K, Rasing I, et al.

    Alzheimer's & dementia : the journal of the Alzheimer's Association 2024; (20(11)):7518-7528 doi:10.1002/alz.14171.

    PMID: 39387105
  6. 6

    Cognitive decline in Dutch-type hereditary and sporadic cerebral amyloid angiopathy: a 5-year follow-up study.

    van Dort R, van Stek-Smits VCJ, Schriemer SE, et al.

    Alzheimer's & dementia : the journal of the Alzheimer's Association 2026; (22(7)):e71629 doi:10.1002/alz.71629.

    PMID: 42360287
  7. 7

    Longitudinal Progression of Magnetic Resonance Imaging Markers and Cognition in Dutch-Type Hereditary Cerebral Amyloid Angiopathy.

    van Dijk SE, van der Grond J, Lak J, et al.

    Stroke 2022; (53(6)):2006-2015 doi:10.1161/STROKEAHA.121.035826.

    PMID: 35360926
  8. 8

    Diagnosis and management of cerebral amyloid angiopathy: a scientific statement from the International CAA Association and the World Stroke Organization.

    Cordonnier C, Klijn C, Smith EE, et al.

    International journal of stroke : official journal of the International Stroke Society 2025; (20(8)):949-967 doi:10.1177/17474930251365861.

    PMID: 40721902
  9. 9

    Cortical superficial siderosis predicts early recurrent lobar hemorrhage.

    Roongpiboonsopit D, Charidimou A, William CM, et al.

    Neurology 2016; (87(18)):1863-1870 doi:10.1212/WNL.0000000000003281.

    PMID: 27694268
  10. 10

    Risk factors for recurrent cerebral amyloid angiopathy-related intracerebral hemorrhage.

    Jia X, Bo M, Zhao H, et al.

    Frontiers in neurology 2023; (14()):1265693 doi:10.3389/fneur.2023.1265693.

    PMID: 38020625
  11. 11

    Convexity subarachnoid hemorrhage in lobar intracerebral hemorrhage: A prognostic marker.

    Raposo N, Charidimou A, Roongpiboonsopit D, et al.

    Neurology 2020; (94(9)):e968-e977 doi:10.1212/WNL.0000000000009036.

    PMID: 32019785
  12. 12

    Cerebral amyloid angiopathy-related inflammation: current status and future implications.

    Wu JJ, Yao M, Ni J

    Chinese medical journal 2021; (134(6)):646-654 doi:10.1097/CM9.0000000000001427.

    PMID: 33625036
  13. 13

    Posterior confluent white matter hyperintensities and intracerebral hemorrhage recurrence risk in patients with cerebral amyloid angiopathy.

    Liu J, Liu F, Wang Z, et al.

    Frontiers in neurology 2026; (17()):1767088 doi:10.3389/fneur.2026.1767088.

    PMID: 41908271
  14. 14

    Spatial and temporal intracerebral hemorrhage patterns in Dutch-type hereditary cerebral amyloid angiopathy.

    Voigt S, Amlal S, Koemans EA, et al.

    International journal of stroke : official journal of the International Stroke Society 2022; (17(7)):793-798 doi:10.1177/17474930211057022.

    PMID: 34791949
  15. 15

    Brain hemorrhage recurrence, small vessel disease type, and cerebral microbleeds: A meta-analysis.

    Charidimou A, Imaizumi T, Moulin S, et al.

    Neurology 2017; (89(8)):820-829 doi:10.1212/WNL.0000000000004259.

    PMID: 28747441
  16. 16

    Scanxiety and quality of life around follow-up imaging in patients with unruptured intracranial aneurysms: a prospective cohort study.

    Kamphuis MJ, van der Kamp LT, van Eijk RPA, et al.

    European radiology 2024; (34(9)):6018-6025 doi:10.1007/s00330-024-10602-0.

    PMID: 38311702
  17. 17

    Measuring "Scanxiety": A Systematic Review and Symptom Coverage Analysis of Commonly Used Measures.

    Bullock K, Rawlings GH, Lee G, et al.

    Radiography (London, England : 1995) 2026; (32(6)):103488 doi:10.1016/j.radi.2026.103488.

    PMID: 42485752
  18. 18

    Characterizing surveillance-associated anxiety following curative-intent surgery for gastrointestinal cancer: a mixed methods approach.

    Bath NM, Khatri R, Quinn PL, et al.

    Journal of cancer survivorship : research and practice 2025; doi:10.1007/s11764-025-01781-w.

    PMID: 40299240
  19. 19

    The experience of patients participating in a small randomised control trial that explored two different interventions to reduce anxiety prior to an MRI scan.

    Tugwell-Allsup J, Pritchard AW

    Radiography (London, England : 1995) 2018; (24(2)):130-136 doi:10.1016/j.radi.2017.11.001.

    PMID: 29605109
  20. 20

    Communication and Team Interactions to Improve Patient Experiences, Quality of Care, and Throughput in MRI.

    Ajam AA, Tahir S, Makary MS, et al.

    Topics in magnetic resonance imaging : TMRI 2020; (29(3)):131-134 doi:10.1097/RMR.0000000000000242.

    PMID: 32568975
  21. 21

    Screening for Brain Metastases in Patients With NSCLC: A Qualitative Study on the Psychologic Impact of Being Diagnosed With Asymptomatic Brain Metastases.

    Schoenmaekers JJAO, Bruinsma J, Wolfs C, et al.

    JTO clinical and research reports 2022; (3(10)):100401 doi:10.1016/j.jtocrr.2022.100401.

    PMID: 36188631
  22. 22

    "Scanxiety" and a sense of control: the perspective of lung cancer survivors and their caregivers on follow-up - a qualitative study.

    Seibel K, Sauer B, Wagner B, Becker G

    BMC psychology 2023; (11(1)):119 doi:10.1186/s40359-023-01151-0.

    PMID: 37069692

This page explains MRI monitoring and long-term care for APP-related amyloidosis for informational purposes only and does not constitute medical advice. Your neurologist and radiologist should interpret your scans and advise you about your personal bleeding risk and follow-up schedule.